Product launch success and FDA approval timelines - new generic approvals and branded product line extensions drive revenue growth expectations
Acquisition integration progress and synergy realization - ANIP has been acquisitive, and execution on cost synergies directly impacts margin trajectory
Generic drug pricing environment - industry-wide pricing pressure or stabilization affects ~50-60% of revenue base
Cortrophin Gel and branded specialty product performance - high-margin products disproportionately impact profitability despite smaller revenue contribution
low - Pharmaceutical demand is largely non-discretionary and driven by medical necessity rather than economic conditions. Prescription drug volumes remain stable through recessions as patients continue chronic disease management. However, generic drug pricing can face pressure during economic downturns as payers (insurers, PBMs) negotiate more aggressively, and branded specialty products may see slower volume growth if patients delay elective treatments. The company's exposure to hospital-administered products creates modest cyclical sensitivity to elective procedure volumes.
Rising interest rates have moderate negative impact through two channels: (1) ANIP carries $230M+ in debt (0.64 D/E ratio), so higher rates increase interest expense and reduce cash available for growth investments or debt paydown; (2) as a growth-stage company trading at 2.1x sales with negative net margins, higher rates compress valuation multiples as investors demand higher returns and shift toward profitable, cash-generative businesses. The 10-year Treasury yield serves as the discount rate for future earnings, particularly impactful for companies in investment mode.
Generic drug pricing erosion - industry-wide pressure from PBM consolidation, increased competition from low-cost manufacturers (including international), and regulatory scrutiny on drug pricing could compress margins on 50-60% of revenue base
FDA regulatory risk - manufacturing quality issues, warning letters, or approval delays could disrupt supply and damage reputation; pharmaceutical manufacturing faces stringent cGMP requirements
Patent litigation and intellectual property challenges - generic drug launches face potential patent infringement suits from branded manufacturers, creating launch delays and legal costs
growth - The stock attracts growth-oriented investors focused on revenue expansion (26% YoY), margin improvement potential, and acquisition-driven scale. Despite negative current profitability, the 59% gross margin and improving operating leverage profile appeal to investors betting on turnaround execution. The 33% one-year return despite recent pullback (-13% six-month) suggests momentum investors also participate. Not suitable for income investors (no dividend) or conservative value investors (negative earnings, elevated valuation multiples). Typical holders include healthcare-focused funds, small-cap growth managers, and event-driven investors playing acquisition synergies.
Trend
+0.5% vs SMA 50 · -6.5% vs SMA 200
Momentum
Heavy distribution on elevated volume — institutions appear to be exiting. Squeeze setups unlikely while selling pressure persists.
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
ANALYST ESTIMATES
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2025 | $867.4M $866.4M–$868.1M | — | $7.54 | — | ±1% | High6 |
FY2026(current) | $1.1B $1.1B–$1.2B | ▲ +29.4% | $9.35 | ▲ +24.1% | ±4% | High5 |
FY2027 | $1.2B $1.2B–$1.3B | ▲ +11.2% | $10.76 | ▲ +15.1% | ±7% | High5 |
INSTITUTIONAL OWNERSHIP
ANIP News
About
ani pharmaceuticals is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals. we focus on niche and high barrier to entry opportunities including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. our two pharmaceutical manufacturing facilities located in baudette, minnesota are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. our objective is to create long term shareholder value by building a sustainable and growing base business in generic and mature brand pharmaceutical products while advancing an opportunity to re-commercialize cortrophin gel and cortrophin-zinc.
| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
ANIP◀ | $78.01 | -1.97% | $1.8B | 18.2 | +4378.3% | 886.8% | 1500 |
| $66.13 | -5.07% | $13.0B | — | +12626.1% | -14525.8% | 1500 | |
| $94.92 | -3.79% | $12.6B | — | +3288.2% | -4239.0% | 1500 | |
| $523.69 | -3.00% | $12.1B | — | +43205.3% | -3008.0% | 1500 | |
| $227.72 | -1.96% | $11.7B | — | +6554.5% | -2868.8% | 1500 | |
| $57.90 | -0.86% | $11.2B | 50.3 | +1459.3% | 147.7% | 1500 | |
| $76.67 | -3.79% | $10.8B | — | +2325815.3% | -19.7% | 1500 | |
| Sector avg | — | -2.92% | — | 34.3 | +342475.3% | -3375.2% | 1500 |